Search research articles
Contact Us
Filters
Showing results (81-90 of 94) with videos related to
Page
of 10
Sort By:
Circulation
|
June 3, 1998
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators
N S Kleiman, A M Lincoff, D J Kereiakes, et al.
Journal of the American College of Cardiology
|
May 15, 1998
Cost of cardiac care in the three years after coronary catheterization in a contained care system: critical determinants and implications
S G Ellis, K J Brown, R Ellert, et al.
The New England Journal of Medicine
|
August 31, 1995
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
L Pilote, R M Califf, S Sapp, et al.
Journal of the American College of Cardiology
|
June 23, 2001
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
K M Anderson, R M Califf, G W Stone, et al.
The American Journal of Cardiology
|
July 22, 1998
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade
S Ghaffari, D J Kereiakes, A M Lincoff, et al.
Circulation
|
December 22, 1998
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
D F Kong, R M Califf, D P Miller, et al.
Circulation
|
July 1, 1997
End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators
R Q Migrino, J B Young, S G Ellis, et al.
Journal of the American College of Cardiology
|
January 13, 1998
Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries
E B Sgarbossa, S L Pinski, E J Topol, et al.
JAMA
|
August 13, 1997
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication
E J Topol, J J Ferguson, H F Weisman, et al.
Journal of the American College of Cardiology
|
July 21, 1998
Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications
M K Chung, R A Schweikert, B L Wilkoff, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 94) with videos related to
Sort By:
Page
of 10
Circulation
|
June 3, 1998
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators
N S Kleiman, A M Lincoff, D J Kereiakes, et al.
Journal of the American College of Cardiology
|
May 15, 1998
Cost of cardiac care in the three years after coronary catheterization in a contained care system: critical determinants and implications
S G Ellis, K J Brown, R Ellert, et al.
The New England Journal of Medicine
|
August 31, 1995
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
L Pilote, R M Califf, S Sapp, et al.
Journal of the American College of Cardiology
|
June 23, 2001
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
K M Anderson, R M Califf, G W Stone, et al.
The American Journal of Cardiology
|
July 22, 1998
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade
S Ghaffari, D J Kereiakes, A M Lincoff, et al.
Circulation
|
December 22, 1998
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
D F Kong, R M Califf, D P Miller, et al.
Circulation
|
July 1, 1997
End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators
R Q Migrino, J B Young, S G Ellis, et al.
Journal of the American College of Cardiology
|
January 13, 1998
Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries
E B Sgarbossa, S L Pinski, E J Topol, et al.
JAMA
|
August 13, 1997
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication
E J Topol, J J Ferguson, H F Weisman, et al.
Journal of the American College of Cardiology
|
July 21, 1998
Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications
M K Chung, R A Schweikert, B L Wilkoff, et al.
Page
of 10